DAY ONE BIOPHARMACEUTICALS INC. - COMMON STOCK

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

07 Aug 2023 16:30:00 By Nasdaq GlobeNewswire

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

12 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Day One Announces Pricing of Public Offering of Common Stock

06 Jun 2023 22:31:14 By Nasdaq GlobeNewswire

Day One Announces Proposed Public Offering of Common Stock

06 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

04 Jun 2023 12:45:00 By Nasdaq GlobeNewswire

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

30 May 2023 08:00:00 By Nasdaq GlobeNewswire

CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

25 May 2023 20:30:53 By Nasdaq GlobeNewswire

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

25 May 2023 17:00:00 By Nasdaq GlobeNewswire

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

01 May 2023 09:00:00 By Nasdaq GlobeNewswire

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

26 Apr 2023 09:31:48 By Nasdaq GlobeNewswire

Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress

12 Apr 2023 08:00:38 By Nasdaq GlobeNewswire

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

06 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

Day One to Participate in the Cowen 43rd Annual Health Care Conference

27 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma

08 Jan 2023 17:00:00 By Nasdaq GlobeNewswire

Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference

20 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference

17 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting

11 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Day One Reports Third Quarter 2022 Financial Results and Corporate Progress

07 Nov 2022 16:30:00 By Nasdaq GlobeNewswire

Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)

17 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Day One Appoints Garry Nicholson as Chairman of the Board of Directors

12 Sep 2022 08:30:00 By Nasdaq GlobeNewswire